Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VALEANT PHARMACEUTICALS INTL INC T.VRX

"Valeant Pharmaceuticals is a global specialty pharmaceutical firm with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The firm also has a branded generics business that operates primarily in Latin America, Eastern Europe, and Asia."


TSX:VRX - Post by User

Comment by Defaulteron Jul 13, 2016 1:02pm
93 Views
Post# 25048945

RE:RE: Michael Pearson sells nearly $97M around $20

RE:RE: Michael Pearson sells nearly $97M around $20
BUZZ-Valeant Pharmaceuticals: Ex-CEO sold shares, options worth $96.8 mln- CNBC 1 hour ago - Reuters BUZZ-Valeant Pharmaceuticals: Ex-CEO sold shares, options worth $96.8 mln- CNBC ** Canadian drugmaker's U.S.-listed shares up 3.4 pct at $24.01 ** Former Valeant CEO Michael Pearson sold nearly 5 mln shares and options for a total of $96.8 mln, CNBC reports, citing documents not made public yet (https://cnb.cx/29XNVcZ) ** Pearson left Valeant on May 2 after a year in which the company had drawn scrutiny for its sharp drug price increases, financial relationship with a specialty pharmacy and accounting practices ** Pearson got a $9 mln severance payment and agreed to a consulting agreement worth hundreds of thousands of dollars, according to a document filed with regulators ** Ruane, Cunniff & Goldfarb Inc, the investment firm that runs the Sequoia Fund and once the largest shareholder of Valeant said on Tuesday it exited its position in the embattled Canadian drugmaker by mid-June ** Up to Tuesday's close, stock had fallen 77 pct this year
<< Previous
Bullboard Posts
Next >>